EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas
P.J. Voon(Sarawak General Hospital), B.C. Cho(Yonsei University), Christine Baudelet(Janssen (Belgium)), B. Keam(Seoul National University Hospital), J.M. Bauml, Jessica Dobbs(Janssen (United States)), Ju Le Tan(National Heart Centre Singapore), A.I. Spira(Virginia Cancer Specialists), S.-H. Lee(Samsung Medical Center), Eunice Artis(Janssen (United States)), Bing Xia(Rutgers, The State University of New Jersey), Mehmet Alı Nahıt Şendur(Ankara Yıldırım Beyazıt University), Mirza Rafi Baig(Janssen (United States))
Cited by 1
Related Papers
A recurrent mutation in PALB2 in Finnish cancer families
|Nature|2007|461
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
|Annals of Oncology|2024|81
BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage
|Nature Communications|2021|76